StockNews.com Initiates Coverage on Zevra Therapeutics (NASDAQ:KMPH)
StockNews.com Initiates Coverage on Zevra Therapeutics (NASDAQ:KMPH)
Equities research analysts at StockNews.com began coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report issued on Sunday. The firm set a "hold" rating on the specialty pharmaceutical company's stock.
股票研究分析師在股票新聞網開始覆蓋 澤弗拉治療 (納斯達克:KMPH — 獲得評分) 在星期日發布的研究報告中。該公司對該專業製藥公司的股票設定了「持有」評級。
Zevra Therapeutics Stock Performance
Zevra 治療學股票表現
The business has a 50-day moving average price of $5.46 and a 200 day moving average price of $5.38. Zevra Therapeutics has a 52 week low of $4.00 and a 52 week high of $6.92. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.10 and a current ratio of 10.10.
該業務的 50 天移動平均價為 5.46 美元，200 日移動平均價格為 5.38 美元。澤弗拉治療學擁有 52 周低點 4.00 美元，52 周高點為 6.92 美元。該公司的債務與權益比率為 0.14，快速比率為 10.10，流動比率為 10.10。
Insider Transactions at Zevra Therapeutics
Zevra 治療學的內幕交易
In other news, CEO Richard W. Pascoe bought 9,500 shares of the company's stock in a transaction dated Friday, January 13th. The shares were purchased at an average price of $5.44 per share, for a total transaction of $51,680.00. Following the completion of the purchase, the chief executive officer now owns 19,973 shares in the company, valued at approximately $108,653.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.10% of the company's stock.
在其他消息中，首席執行官理查德 ·W· 帕斯科在 1 月 13 日（星期五）的交易中購買了該公司股票的 9,500 股。這些股份以每股 5.44 美元的平均價格購入，總交易額為 51,680.00 美元。購買完成後，首席執行官現擁有該公司 19,973 股股份，價值約 108,653.12 元。該交易在與 SEC 合法提交的文件中披露，該文件可在以下網址獲得 證券交易所網站。業內人士擁有公司股票的 1.10％。
Institutional Inflows and Outflows
機構流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMPH. UBS Group AG bought a new position in Zevra Therapeutics during the second quarter valued at approximately $26,000. Verition Fund Management LLC bought a new position in Zevra Therapeutics during the fourth quarter valued at approximately $46,000. Invesco Ltd. bought a new position in Zevra Therapeutics during the first quarter valued at approximately $51,000. Kingsview Wealth Management LLC bought a new position in Zevra Therapeutics during the second quarter valued at approximately $54,000. Finally, HRT Financial LP bought a new position in Zevra Therapeutics during the fourth quarter valued at approximately $66,000. Institutional investors own 19.39% of the company's stock.
一些對沖基金和其他機構投資者最近增加或減少了他們在 KMPH 的股份。瑞銀集團股份有限公司在第二季度購買了 Zevra 治療學的新倉位，價值約為 26,000 美元。Verition 基金管理有限責任公司在第四季度收購了 Zevra 治療學的新職位，價值約為 46,000 美元。景順有限公司於第一季度買入 Zevra 治療的新倉位，價值約為 $51,000。金景財富管理有限責任公司在第二季度收購了 Zevra 治療的新位置，價值約為 54,000 美元。最後，HRT 金融有限公司在第四季度購買了 Zevra 治療學的新頭寸，價值約為 66,000 美元。機構投資者擁有公司股票的 19.39%。
About Zevra Therapeutics
關於澤弗拉治療
(Get Rating)
(取得評分)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
KemPharm, Inc 是一家臨床階段的專業製藥公司，從事專有前藥的發現和開發。它通過其稱為配體活化療法的平台技術，專注於治療嚴重的醫療條件，例如注意力缺陷多動障礙，疼痛和其他中樞神經系統疾病。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- 獲取有關澤弗拉治療學（KMPH）的研究報告的免費副本
- 市場節拍週的回顧 — 3 月 27 日 — 3/31
- 什麼是黃金 IRA 退休賬戶，它是一項可行的投資嗎？
- 是 Braze 公司準備火箭更高嗎？
- 穆倫汽車製造交貨；短擠壓成為可能
- 前線可以保持這種勢頭嗎？
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Zevra 治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Zevra 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。